The United Kingdom and the United States have secured a important trade agreement that will ensure no import taxes on UK pharmaceutical shipments entering the American market.
Agreement Details of the Accord
As part of the deal, the UK has pledged to boost expenditure on drugs through the public health system. This pledge guarantees that duties on these vital goods will stay at nothing for a timeframe of three years.
This deal is in response to previous statements to dramatically increase import taxes on patented pharmaceutical products, with potential rates mentioned up to 100%.
"This deal with the UK reinforces the international landscape for new treatments and establishes much-needed fairness to U.S.–U.K. medicine commerce," an announcement said.
Trade Importance
Medicines are one of the Britain's biggest export categories to the US, which is by far the largest market for leading companies like GSK and AstraZeneca.
Statistics show that in the one-year period to the end of last September, the UK shipped medicines worth billions to the US. This figure represented 17.4% of all goods exports in that span.
"This deal safeguards work, boosts investment and facilitates the UK to become a global hub for biotech and pharma," the Business and Trade Secretary commented.
Detailed British Pledges
The agreement involves several specific pledges from the United Kingdom:
- Revised Affordability Limit: The UK will lift the price threshold at which it considers new therapies to be prohibitively costly by twenty-five percent.
- Increased NHS Spending: There is a aim to increase overall public funding on treatments from 0.3% of Gross Domestic Product to 0.6 percent over the next decade.
- Refund Ceiling: The percentage pharmaceutical firms must return to the NHS to control costs will be capped at 15%. Previously, refunds topped 20%.
Industry Background
This agreement takes place against a long-running dispute between the pharmaceutical industry and the UK government over medicine costs and regulatory access.
This friction were exacerbated by assertions that American consumers were charged a premium for the same drugs than consumers in the UK and Europe.
In recent months, several major manufacturing plans in the UK have been paused or cancelled, while substantial expansions have been pledged toward American operations.
One official stated that the NHS needed to increase expenditure on drugs, noting that its expenditure on drugs had decreased as a share of its total funding over the previous ten-year period.
